🔥 Turbo-Stock

SOUN is the most established voice AI pure-play: revenue $184M TTM (+80% YoY), OASYS agentic platform launched, LivePerson acquisition closed, named ISG Leader 2026. HC Wainwright $26 target (+310% from $6.34). Main risk: down 30% YTD due to insider fiduciary investigation + valuation concern (15x P/S). 39% short interest = short squeeze fuel. Moon case: EBITDA breakeven H2 2026 + auto sector AI contract wave.

Recursion's AI-driven drug discovery platform now has a real near-term regulatory storyline: REC-4881 showed strong Phase 2 efficacy in familial adenomatous polyposis (FAP), a rare genetic condition, and the FDA is actively engaged on a potential registrational pathway — an update is expected 2H26. REC-4539 (LSD1 inhibitor) just dosed its first Phase 1 patient. Q1 2026 beat estimates and cash burn came in "significantly reduced," with guidance for under $390M burn supporting runway into early 2028 without new financing — a real de-risking versus the typical cash-burning clinical biotech. Morgan Stanley just raised its target to $5.50; other analysts cite a wider range up to $9.

SERV is a ค่าขนม-grade autonomous delivery robot play backed by NVIDIA and Uber. Q1 2026 revenue +578% YoY, 2026 guidance $26M, expanding beyond food into laundry (NoScrubs). Moon case: scale to 10K+ robot fleet. Bear case: dilution ($300M shelf) crushes equity before profitability.

Vera's atacicept has an FDA PDUFA decision due July 7, 2026 — five days from today — for accelerated approval in IgA Nephropathy. Phase 3 ORIGIN data hit its primary endpoint clean (46% proteinuria reduction vs baseline). Goldman Sachs raised its target to $95 (+177%) citing favorable pricing precedent after Travere's Filspari won a broader-than-expected FSGS label in April. This is a true binary event: a clean approval likely re-rates VERA toward the Goldman target or beyond given pipeline optionality (PIONEER trial in membranous nephropathy/FSGS/MCD); a CRL would crash the stock 50%+ same day. Size for the binary, not the trend.

This is a genuine fundamentals-vs-technicals divergence. Since our Jun 26 report, Ondas posted Q1 revenue of $50.1M (huge YoY growth), grew backlog to $457M, already booked over $110M in Q2 orders, raised FY26 guidance to at least $390M, disclosed a $4.3B pipeline across 45+ program submissions, and secured a new $40M+ defense order in late June — yet the stock is down ~41% because CEO Eric Brock sold $31.9M of shares and Omnisys-linked holders sold ~3.4M more. Wall Street's 6-analyst consensus target is $19.83 — 2.5x the current price. If the insider-selling overhang clears without new negative news, this looks like a better entry than our prior report at a much higher price.

BTQ builds post-quantum cryptography infrastructure — QCIM (a quantum-secure compute-in-memory chip), QSSN (quantum-safe stablecoin infrastructure for banks/payment providers), and Bitcoin Quantum. The June 22, 2026 White House executive orders on quantum leadership and cryptographic security directly target BTQ's core business: moving federal systems to NIST-approved post-quantum cryptography, with CNSA 2.0 compliance deadlines running 2027-2035. The stock is down ~76% from its October 2025 all-time high of $22 CAD, and next earnings/corporate update (Aug 13) is the nearest hard catalyst for QCIM commercialization progress.

POET's thesis took a real hit: Marvell (which acquired Celestial AI) canceled all purchase orders sourced through that relationship on Apr 23, 2026, alleging a confidentiality breach — and POET now faces related legal action. The stock is down ~19% from our Jun 24 report as a result. But the company hasn't stood still: a Lumilens supply deal (initial $50M PO, framework up to $500M+ over 5 years), a Lessengers joint development for a 1.6T 2x DR4 transceiver (samples targeted Q2 2026), and a LITEON strategic collaboration all point to a more diversified — if less singular — optical interconnect story. This is now a real turnaround/re-proof bet, not a clean momentum play.

FLY is the #2 pure-play US space launch company — at 50% discount to its own secondary offering price 25 days ago. SpaceX IPO capital rotation crushed the stock; analysts say the selloff was unwarranted. Revenue $440M FY2026 guide (+175% YoY). Buy consensus (9 analysts), avg target $48.22 (+97%). TODAY acquired Space-ng for autonomous ops. 52-week high $73.80 = +202% from here.

NioCorp's Elk Creek project holds the second-largest indicated rare-earth resource in the US (niobium, scandium, titanium) and is exactly the kind of asset the government's $12B "Project Vault" critical-minerals stockpile initiative is designed to fund. The company already has a $10M DPA Title III award and a preliminary term sheet for up to $800M in EXIM Bank debt financing, now working through EXIM's technical due diligence (TRC-2/TRC-3). A finalized EXIM commitment — no confirmed date, but the process is actively advancing in 2026 — would fully de-risk construction financing and is the clear binary catalyst. China's rare-earth export restrictions and the Trump-Xi summit have made this a live policy theme all year.

QUBT is a photonic quantum computing + defense-AI play that just closed a $73.1M acquisition of NHanced Semiconductors, with an initial commercial commitment for up to 100 NeuraWave systems (potential value $10M+). The stock wasn't part of the May 2026 $2B federal quantum equity-stake program (which sent D-Wave, Rigetti, and Infleqtion up 30%+ in a single day), but the same policy tailwind — including June 22 White House executive orders on quantum leadership — is structural and sector-wide. Q2 earnings Aug 19 is the next hard date; a further government funding round or a NeuraWave contract win is the real moonshot trigger.

Palladyne AI just won U.S. Army contracts (June 17-23) for SwarmOS autonomous swarm software + Gremlin-X mini-bomber UAV under the Army's Competitive Disruptive Applications program. SwarmOS lets 1 operator command an entire heterogeneous drone fleet simultaneously — the AI command layer every defense force needs. Market cap is only $280M vs an autonomous drone market projected at $50B+. The Northern Strike 26-2 exercise (9,000+ participants) is the next live-fire validation catalyst. Northland set a $15 target (138% upside) in June. Moon case: multi-branch DoD adoption = $30+ (375%).

BTBT is a dual-catalyst moonshot: ETH treasury play (holds ETH + staking) AND AI/HPC infrastructure via WhiteFiber subsidiary. Strong Buy from HC Wainwright ($7 target = +222%), B. Riley ($4 = +84%). Moon case: WhiteFiber IPO/re-rate + ETH bull cycle = $8–10 (+268–361%). Bear case: ETH crashes + AI data center ramp slower than expected. 5 analysts, all Strong Buy.

Archer just became the first eVTOL manufacturer to complete Phase 3 of 4 in the FAA Type Certification process and joined the White House eVTOL Integration Pilot Program — putting it on track to start US commercial operations later in 2026. Late-June addition to the Russell 2000/2500/3000 Value indices is driving passive-fund inflows on top of the certification news. The balance sheet is strong ($951M cash, $1.78B including short-term investments), but revenue is still nearly zero ($1.6M Q1) against a $217.7M quarterly net loss — this remains a binary bet on Phase 4 completion and the actual start of commercial flights, not a business generating cash today.

NANO Nuclear's KRONOS MMR™ is a 15MWe microreactor small enough to deploy at a data center, remote military base, or university campus. On June 23, 2026, the NRC initiated formal review activities with University of Illinois Urbana-Champaign — the first step in a regulatory path that ends in a construction permit. SMCI signed a MOU to explore co-packaged nuclear power solutions for data centers. Roth Capital has a $45 target (128% upside from $19.76). Moon case: NRC approval + 1 hyperscaler deployment contract = $60+ (203%+).

Redwire is the picks-and-shovels of space infrastructure — building solar arrays for the ISS, power systems for Lunar Gateway, and in-space manufacturing capabilities. The Golden Dome Initiative ($151B missile defense program) is a direct opportunity for Redwire's space-based ISR and sensor systems. EU/ESA contracts provide international revenue diversification. Analysts have targets from $15 (37% upside) to $24 (120% upside). Moon case: major Golden Dome contract win + Redwire becomes the Boeing Defense of space hardware = $44 (302%).

Capricor's deramiocel — a cell therapy targeting cardiomyopathy in Duchenne Muscular Dystrophy, a fatal disease with no approved treatment for this specific complication — faces an FDA Advisory Committee vote Jul 29, 2026 followed by a PDUFA decision Aug 22. Analysts rate it Strong Buy with a $53.60 target (+116%). The stock's own 52-week range ($4.30 to $40.37) already shows this name can move 800%+ on trial readouts alone — a positive AdCom vote plus approval is a genuinely two-stage binary catalyst over the next 8 weeks.

⚠️ Market cap caveat: RGTI at $6.1B slightly exceeds turbo screen max ($5B). Included for exceptional asymmetry: stock is 68% below its $58.15 52-week high, making the return-to-ATH scenario a 215% gain. The Presidential Executive Order on quantum computing signed June 23, 2026 creates direct federal procurement mandates — agencies must prioritize US quantum systems. Rigetti's Lyra QPU (100+ qubits, Q4 2026) is the biggest hardware milestone in company history. Government contracts + academic partnerships = path to $31+ (68% upside) base case. Moon = $58 ATH revisit at 215%.

⚠️ NOTE: ACMR market cap $7.2B exceeds typical Turbo profile ($5B max) and analysts' average PT $88 is BELOW current price. This is a pure momentum + China semiconductor upcycle play. ACMR dominates China WFE market and is executing: Q1 2026 revenue +34% YoY, EPS $0.34 vs $0.20 estimate. The moon case requires China's $150B+ semiconductor buildout to sustain AND ACMR to expand internationally — possible but a 3–5 year thesis. Roth Capital $125 target suggests 20% near-term upside; 300%+ requires China semicon boom + re-rating to premium multiple. Position max 2–3% — ค่าขนม ที่ risk/reward ปานกลาง.

BlackSky operates an AI-powered satellite intelligence platform — real-time Earth observation with sub-hourly revisit rates, processed by AI models for military, government, and commercial customers. In April 2026, BlackSky won a $30M defense contract extension for real-time ISR (Intelligence, Surveillance, Reconnaissance). The Golden Dome initiative explicitly requires space-based ISR sensor layers — BlackSky's core capability. Analyst targets range $30-42 (20-68% upside). Moon case: Black Sky wins a large Golden Dome ISR prime or major DoD intelligence contract = $75 (201% upside).